Abstract: Gypsum-based molding materials are customized by hydrating the molding material to workable (malleable) consistency with a moistening solution containing 0.001 to 60% polytetrafluoroethylene. The addition of latex results in a more flowable material.
Abstract: When used as a biocide on newly butchered chickens, chlorine dioxide at concentrations of 12 to 50 ppm is effective at temperatures of 35° C. to 90° C. with 15 ppm being very effective at temperatures of 45° C. to 60° C. Chlorine dioxide in about 50° C. water did not off gas chlorine dioxide at a concentration of 50 ppm.
Abstract: The present invention provides a means of selectively killing epithelial cell carcinomas by administering a CXCR4-specific sequence of the Gp120 protein or Nef proteins or the proteins themselves (the modulators) such as that found in strains HIV-1, HIV-2, SIV, or FIV CXCR4-specific Gp 120 sequences or Nef proteins or sequences may be delivered to the mucosa or systemically. The mucosal means of application include oral, intranasal, ocular, intravaginal, rectal, and/or intraurethral administration in liquid or particulate form.
March 20, 2003
Date of Patent:
December 25, 2007
Morehouse School of Medicine
Vincent C. Bond, James Lillard, Ming Bo Huang, Harvey Bumpers, Michael Powell
Abstract: Solid dosage forms are produced by absorbing solutions of drug:cyclodextrin inclusion complexes on absorbing matrices and then drying. The matrices may, but need not, disintegrate in water. The resulting forms are suitable for oral or sublingual administration, and also can be used in topical administrations to mucosa covered tissues. They are particularly suitable for sublingual administration because the eluted, nondisintegrated matrix (e.g., absorbing paper) can be recovered and checked for completion of elution. This enables documentation that effective absorption occurred from the mouth cavity.
Abstract: This invention provides a method of measuring oxidative response of cells without recourse to preparation of cell culture. The process involves: 1) preparing suspensions of cells from a living host in isotonic solutions, 2) preparing samples of test materials in isotonic solution containing tagged choline, 3) adding the cells suspension prepared in step 1 to the samples prepared in step 2, 4) incubating the product of step 3 with shaking for 2-90 minutes, 5) extracting and drying the lipid phase from the product of step 4, and 6) subjecting the product of step 5 to a scintillation counter to measure choline which has been incorporated into phosphatidylcholine (PC). An increase in incorporation of choline into PC in the short term indicates oxidative stress or free radical induced damage. Because the method of the invention using the cell isolates does not require the expense of cell culture with concomitant expense and possibility of cell change, it is particularly useful for clinical evaluation.
Abstract: Peptides have been discovered which are capable of binding to and internalizing with the human transferrin receptor (hTfR). The sequences HAIYPRH (Seq. ID No. 1) and THRPPMWSPVWP (Seq. ID No. 2) are capable of binding to and internalizing with the human transferrin receptor. When these molecules were fused with other molecules, the fusion product was internalized in cells expressing hTfR. The sequences have use for targeting other peptides and proteins into cells expressing hTfR.
November 29, 2001
Date of Patent:
June 1, 2004
The UAB Research Foundation
Jeffrey A. Engler, Jae Hwy Lee, James F. Collawn, Bryan A. Moore
Abstract: Generally, the method for preventing or relieving discomfort in the ears arising from congestion and/or obstruction of in the eustachian tubes comprising or changes in middle ear pressure relative to atmospheric pressure arising from environmental conditions in an individual need of prevention or relief from discomfort in the ears comprises the steps of: 1) administering a solution of 1.5%-3.5% (preferably 2-3%) sodium chloride solution having a pH of about 6 to 7.8 (preferably 6.5-7.5) in an aqueous solution as a spray or mist into the nose, 2) minimizing discharge of the solution from the nose for at least 5 seconds, then 3) evacuating the nose under pressure.
Abstract: Certain mixtures of cyclodextrin derivatives, which were synthesized in mildly basic conditions, can be separated into mixtures that crystallize easily and mixtures of similar composition, which remain amorphous. Thus, it is possible to obtain the particular advantages of crystalline and/or amorphous state components from one reaction product. Both crystalline and amorphous components of the product have good ability to form inclusion complexes.
Abstract: Co-administration of a channel blocking epithelial sodium channel (ENaC) blocker in conjunction with a mineralocorticoid receptor inhibitor makes it possible to achieve desired lowering of blood pressure with use in the range of 20% to 75% or less of the presently used dosage of the mineralocorticoid receptor inhibitor (MRI), thus avoiding many of the deleterious side effects usually associated with administration of an MRI. As little as 10% of the usual dosage of MRI may, in some cases, be efficacious. The most commonly used ENaC blocker now in use is amiloride. The most commonly used inhibitors of the mineralocorticoid receptor are precursors of canrenone.
Abstract: Novel compounds are chiral compounds which are conformationally restricted polyamine analogues for use in imaging and for therapeutic use in treatment of tumors. These analogues diminish the ability to aggregate DNA seen in the parent polyamines. The invention provides for synthesis of a library of analogues with fine structural modifications which retain restriction and conservation of the molecular weight of the parent polyamines.
Abstract: A method is disclosed for the potentiation of formation of inclusion complexes of electroneutral and anionic compounds. Included are compositions containing complexes of two different cyclodextrin species. New complexes containing as guest molecules active agents which have been first converted to salts are also disclosed.
Abstract: A needle is attached to a connector portion having a common passage with an an arm with a lumen that has a one-way valve which prevents flow of fluid from the needle through the lumen of the arm which acts as a conduit for insertion of a wire into the channel of the needle that has been inserted into a blood vessel. The connector portion having the arm may be provided as a separable adapter for use with a conventional needle hub or may be a part of the needle assembly.
Abstract: An improved method for detection of total coliforms and E. coli comprising a broth containing an ingredient that will encourage growth and repair of injured coliforms, buffers to maintain a pH in the range of 6.5-8, at least one agent that suppresses growth of gram positive cocci and spore-forming organisms, at least one active agent that will suppress growth of non-coliform gram negative bacteria, and at least one chromogen or fluorogen has been used effectively and is cost effective. In the preferred embodiment, both a fluorogen and chromogen were used. Preferred methods include use of filter and/or plates containing the growth-promoting ingredients and the indicators.
August 5, 1999
Date of Patent:
October 23, 2001
The United States of America as represented by the
Administrator of the U.S. Environmental Protection Agency
Kristen P. Brenner, Clifford C. Rankin, Yvette R. Roybal-McKenna, Alfred P. Dufour
Abstract: Bioavailability of lead and other heavy metals in the environment may be reduced by addition of microorganisms which sequester lead from the environment in the presence of phosphate. The microorganisms are highly mobile and are, therefore, capable of scavenging a material for lead, which they then sequester. The method basically consists of reducing bioavailability of lead in the environment by addition of Pseudomonas aeruginosa strain CHL004 (ATCC 55937) to said environment in the presence of phosphate which contains at least stoichiometric equivalent amounts of phosphate to lead.
April 26, 1999
Date of Patent:
October 9, 2001
The United States of America as represented by the
Administrator of the United States Environmental Protection
Wendy J. Davis-Hoover, Stephen J. Vesper
Abstract: This invention provides a vaccine for protecting swine against influenza virus by administration of an attenuated recombinant vaccinia virus containing inserts of the hemagglutinin (HA) and nucleoprotein (NP) genes of influenza virus, which express the hemagglutinin and nucleoprotein proteins.
Abstract: The method of the invention involves treating cellulosic vegetable matter (the “Feed Stocks”) for the selective recovery of lignin (when present in the feed-stock), cellulose and hemi-celluloses by: (1) reducing the material to be processed to an appropriate size; (2) adjusting the moisture content of the ligno-cellulosic feed stock to 15 percent to 30 percent water; (3) impregnating the ligno-cellulosic feed stock with an extraction liquor containing a glycol and an organic or Lewis acid; (4) rapid heating of said impregnated feed stock to a temperature of about 118° C. to about 145° C.; (5) maintaining the desired temperature for about 1 minute to about 6 minutes to solubilize the lignin therefrom (a period of about 2 minutes to about 5 minutes is preferred); (6) stopping the reaction immediately by lowering the temperature to <100° C.
Abstract: This invention provides a device for use in making dental models comprising a tray support a having an opening and a tray having an inferior surface with a projection from said inferior surface of said tray, wherein said projection of said tray fits into said opening in said tray support, said tray support having attached thereto hinge portions which are capable of interaction with hinge portions from a second tray support to form a completed hinge means.
Abstract: This invention provides a method of measuring oxidative response of cells without recourse to preparation of cell culture. The process involves:
1) preparing suspensions of cells from a living host in isotonic solutions,
2) preparing samples of test materials in isotonic solution containing tagged choline,
3) adding the cells suspension prepared in step 1 to the samples prepared in step 2,
4) incubating the product of step 3 with shaking for 2-90 minutes,
5) extracting and drying the lipid phase from the product of step 4, and
6) subjecting the product of step 5 to a scintillation counter to measure choline which has been incorporated into phosphatidylcholine (PC). An increase in incorporation of choline into PC in the short term indicates oxidative stress or free radical induced damage. Because the method of the invention using the cell isolates does not require the expense of cell culture with concomitant expense and possibility of cell change, it is particularly useful for clinical evaluation.
Abstract: Compositions of lymphotactin in cellular immune enhancing amounts may advantageously be administered at very low levels in conjunction with vaccines to provide improved immune response, Suggested dosage such as 1 to 10 .eta.g in small animals and from 10 .mu.g to 10 mg in large mammals may be administered.